OpenScience.ink

2 days ago • Cureus

Effects of Glucagon-Like Peptide-1 Receptor Drugs on Reproductive Health for Obstetrician-GynecologistsGlucagon-Like Peptide-1 Receptor Agonists and Reproductive Health: A Narrative Review for Obstetrician-Gynecologists.

Article

3 days ago • Expert review of respiratory medicine

Sepsis risk in people with COPD and type 2 diabetes linked to new blood sugar treatmentsSepsis risk in patients with COPD and type 2 diabetes mellitus: influence of emerging antihyperglycemic therapies.

Article

4 days ago • Cardiovascular diabetology. Endocrinology reports

AI-based chest x-rays may detect hidden heart relaxation problems in diabetes and obesity and track responses to diabetes medicationsAI-enabled chest x-ray potentially detects subclinical diastolic dysfunction in diabesity and monitors its functional responses to GLP-1 or GLP-1/GIP receptor agonists: initial exploration and proof-of-concept.

Article

5 days ago • Cureus

Changes in Outpatient Use and Dosage of Tirzepatide in Japan Based on National Prescription DataOutpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.

Article

6 days ago • Cureus

Effectiveness and Safety of Two- and Three-Target GLP-1 Drugs for Fatty Liver Disease and Liver InflammationEfficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.

Article

6 days ago • Korean journal of anesthesiology

Korean expert recommendations on stomach ultrasound before anesthesia and anesthesia care for patients using GLP-1 receptor agonist treatmentsKorean consensus-based recommendations for preanesthetic gastric ultrasound and anesthetic considerations for GLP-1 receptor agonist-based therapy: a consensus statement from Clinical Practice Guideline Committee of the Korean Society of Anesthesiologists.

Article

6 days ago • Cureus

Heart Health and Safety of Glucagon-Like Peptide-1 Drugs in Type 2 Diabetes: A Review and Analysis of Clinical TrialsComparative Cardiovascular Outcomes and Safety Profiles of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Trials.

Article

1 week ago • AJNR. American journal of neuroradiology

Glucagon-like Peptide-1 Therapy and Thinking Abilities in Patients Treated for Idiopathic High Brain PressureGlucagon-Like Peptide-1 Receptor Agonist Therapy and Neurocognitive Outcomes in Medically Managed Idiopathic Intracranial Hypertension: A Propensity Score-Matched Cohort Study.

Article

1 week ago • Cureus

GLP-1 Receptor Agonists and Their Potential Role in Treating Substance Use DisordersA Systematic Review and Meta-Analysis Evaluating the Role of GLP-1 Receptor Agonists in Substance Use Disorders.

Article

1 week ago • HIV medicine

Semaglutide improves fatty liver and liver inflammation in people with HIVSemaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study.

Article

1 week ago • Diabetes, obesity & metabolism

Comparing the effects of low-dose tirzepatide (2.5 mg vs 5 mg) for obesity in non-diabetic Japanese adultsLow-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults.

Article

1 week ago • The Journal of nutrition

Diet Quality and Vitamin and Mineral Intake in U.S. Adults Who May Qualify for Weight-Loss DrugsDiet Quality and Micronutrient Intake Among U.S. Adults Eligible for GLP-1 Receptor Agonist Anti-Obesity Medications: A Nationally Representative Analysis.

Article

1 week ago • Biochemical pharmacology

Orforglipron may reduce aortic aneurysm and dissection by blocking a specific cell signaling pathwayOrforglipron alleviates aortic aneurysm and dissection via inhibiting WNT5A noncanonical signaling.

Article

1 week ago • Journal of clinical psychopharmacology

Semaglutide and Similar Drugs for Treating Metabolic Problems Linked to Antipsychotic Use in SchizophreniaSemaglutide and Other GLP-1 Agonists for Antipsychotic-Associated Metabolic Dysfunction in Schizophrenia: A Systematic Review and Meta-Analysis.

Article

1 week ago • Diabetes, obesity & metabolism

Effectiveness and Safety of Weekly Semaglutide 2.0 mg Added to Lower vs Adjusted Insulin Glargine Doses in Overweight People with Type 2 DiabetesEfficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).

Article

1 week ago • Obesity reviews : an official journal of the International Association for the Study of Obesity

How Often People with Overweight or Obesity Do Not Follow GLP-1 Receptor Agonist Treatment: A Review of Clinical TrialsNonadherence to GLP-1 Receptor Agonists Among Individuals With Overweight or Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

1 week ago • Cureus

Possible Reduction of Early Weight Loss with Tirzepatide in a Patient Also Taking Levosulpiride: A Case Report and ExplanationPossible Attenuation of Early Weight Loss During Tirzepatide Therapy in a Patient Treated With Levosulpiride: A Case Report and Mechanistic Hypothesis.

1 week ago • The International journal of eating disorders

Eating Disorder Risk and Screening in Patients Using GLP-1 Receptor Agonists Compared to Weight Loss SurgeryEating Disorder Risk and Screening in Patients Using GLP-1RAs: Lessons Learned From Metabolic and Bariatric Surgery.

1 week ago • Cureus

How Metabolism and Hormones Work Together: A New View on Reproduction and Metabolism in the GLP-1 Treatment EraMetabolic-Hormonal Interplay and the Case for a Reproductive-Metabolic Framework in the Glucagon-Like Peptide-1 (GLP-1) Era.

1 week ago • Chronic diseases and translational medicine

How GLP-1 Receptor Agonists Relate to Stomach Emptying, Aspiration Risk, and Current Guidelines for EndoscopyGLP-1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri-Procedural Guidance.

1 week ago • Singapore medical journal

Recent progress and future directions in managing diabetic kidney diseaseRapidly changing landscape of diabetic kidney disease management: recent advances and the road ahead.

1 week ago • Cureus

Cardiovascular benefits of semaglutide 2.4 mg in people with overweight or obesity: a review of current evidenceEvaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence.

1 week ago • Cureus

Effectiveness and safety of weekly semaglutide compared to daily insulin and similar drugs in adults with type 2 diabetes not controlled by oral medicationsEfficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.

1 week ago • Cureus

Weight Loss After Liraglutide Treatment in a Patient with Smith-Magenis SyndromeWeight Loss Following Liraglutide Therapy in a Patient With Smith-Magenis Syndrome: A Case Report.

1 week ago • AACE endocrinology and diabetes

Changes in Prescriptions of Two Diabetes Medicines for Type 2 Patients from 2014 to 2024Trends in Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon‑Like Peptide‑1 Receptor Agonist Prescription Rates Among Patients With Type 2 Diabetes: An Epic Cosmos Real-World Data Analysis, 2014-2024.

1 week ago • American journal of translational research

Liraglutide and pioglitazone treatment in obese polycystic ovary syndrome and its impact on blood levels of chemerin and visfatinClinical efficacy of liraglutide combined with pioglitazone in obese polycystic ovary syndrome and its effects on the serum chemerin/visfatin ratio.

1 week ago • Pharmacology & therapeutics

Using Biomarkers to Guide Drug Choice and Monitoring in Heart, Kidney, and Metabolic ConditionsBiomarker-guided pharmacotherapy in cardiovascular-kidney-metabolic syndrome: A three-dimensional framework for precision drug selection and monitoring.

2 weeks ago • Mayo Clinic proceedings

Alcohol Use After Treatment with GLP-1 Receptor Agonists in the Cooper Center StudyAlcohol Use Following GLP-1 Receptor Agonist Therapy in the Cooper Center Longitudinal Study.

2 weeks ago • Cardiovascular diabetology. Endocrinology reports

Using SGLT2 inhibitors and GLP-1 receptor agonists together in heart failure patientsConcomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure.

2 weeks ago • Diabetes, obesity & metabolism

Safety Warnings for GLP-1 Receptor Agonists from Multiple Drug Safety Databases (2018–2025) with Bias Checks and Prioritized Risk LevelsSafety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.

← prevpage 13 of 15next →

GLP-1 Therapies Research Papers